<DOC>
	<DOCNO>NCT01449032</DOCNO>
	<brief_summary>Coronary artery disease ( CAD ) common cause death major cause hospital admission acute chest pain . In spite improved treatment still many patient CAD daily attack severe chest pain severely reduced life quality . The investigator establish double-blind placebo-controlled trial patient CAD test efficacy safety treatment adipose derived stem cell improve perfusion heart muscle exercise capacity , reduce patient 's symptom .</brief_summary>
	<brief_title>MesenchYmal STROMAL CELL Therapy Patients With Chronic Myocardial Ischemia ( MyStromalCell Trial )</brief_title>
	<detailed_description>In open single centre pilot study evaluate safety efficacy MSC treatment improve heart muscle perfusion patient chronic CAD . Patients treat MSCs significant increase exercise capacity , reduction angina , angina attack medication life quality 6 month follow-up . For parameter tendency towards improve outcome increase number cell . The treatment MSCs safe . The investigator establish double-blind placebo-controlled trial patient CAD test efficacy safety treatment MSCs improve perfusion heart muscle exercise capacity , reduce patient 's symptom .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>CCS III IV Coronary artery stenosis/occlusion treatable invasive procedure LVEF &gt; 40 % ETT 2 10 min Valvular heart disease FEV1 &lt; 1 Severe systemic disease Acute coronary syndrome &gt; 2 month</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Patients</keyword>
</DOC>